Investor Presentaiton

Company overview Financial review 2022 priorities Appendix References ScemblixⓇ continues strong US uptake and achieves important ex-US regulatory milestones in Q2 1 GROWTH Strong early launch uptake Confident in future growth ✓ $31m Q2 sales driven by patients with resistance/intolerance to other TKIs 1L WW Ph3 study enrolling ahead of plan 44% 3L+ new patient share¹ CHMP positive opinion and rollout ongoing across ex-US markets 16% NBRx share across CML lines of treatment¹ 1. Source: IQVIA Market Sizing "Source of Business", "Product Summary" reports, June 2022 15 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation